Article: article from journal or magazin.
Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes.
European Journal of Immunology
To demonstrate that antibody-guided targeting of antigenic MHC class I-peptide tetramer on tumor cells can render them susceptible to lysis by relevant cytotoxic T lymphocytes (CTL), biotinylated HLA-A*0201/Flu matrix peptide complexes were tetramerized on streptavidin molecules previously coupled to Fab' fragments from monoclonal antibodies (mAb) specific for cell surface markers such as carcinoembryonic antigen (CEA), ErbB-2 or CD20. Flow cytometry analysis showed that coating of the HLA-A2-peptide complexes on the four HLA-A2-negative human cancer lines tested (including a CEA-positive colon carcinoma, an ErbB-2(+) breast carcinoma and two CD20(+) B lymphomas) was entirely dependent upon the specificity of the conjugated antibody fragments. More importantly, HLA-A2-restricted Flu matrix peptide-specific CTL were then found to lyse specifically and efficiently the MHC-coated target cells. These results open the way to the development of new immunotherapy strategies based on antibody targeting of MHC class I-peptide complexes.
Antibodies, Neoplasm/immunology, Antigens, Neoplasm/immunology, Cytotoxicity, Immunologic, Histocompatibility Antigens Class I/immunology, Humans, Immunoconjugates, Immunotherapy, T-Lymphocytes/immunology, Tumor Cells, Cultured
Web of science
Last modification date